This ADC product is composed of an anti-HER2 antibody conjugated via vc linker to Duostatin-3 (trastuzumab-vc-Duostatin-3). It has demonstrated a response in ovarian cancer treatment by a MOA (Mechanism of Action) of inhibiting cell division by blocking of tubulin polymerization.